The effects of empagliflozin vs metformin on endothelial microparticles in overweight/obese women with polycystic ovary syndrome
Context Endothelial microparticles (EMPs) are novel, surrogate biomarkers of endothelial function and have been shown to be elevated in women with polycystic ovary syndrome (PCOS). It remains poorly understood how pharmacological options for managing PCOS affect EMP levels. Objective To characterise...
Saved in:
Published in | Endocrine Connections Vol. 9; no. 6; pp. 563 - 569 |
---|---|
Main Authors | , , , , , , |
Format | Journal Article |
Language | English |
Published |
England
Bioscientifica Ltd
01.06.2020
Bioscientifica |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Context Endothelial microparticles (EMPs) are novel, surrogate biomarkers of endothelial function and have been shown to be elevated in women with polycystic ovary syndrome (PCOS). It remains poorly understood how pharmacological options for managing PCOS affect EMP levels. Objective To characterise and compare the effects of empagliflozin vs metformin on the circulating levels of EMPs in overweight/obese women with PCOS. Methods This was a randomised, comparative, 12-week single-centre trial conducted at the Academic Diabetes, Endocrinology and Metabolism Research Centre, Hull, UK. This analysis includes data from 39 overweight/obese women with PCOS who completed the study and were randomised to empagliflozin (15 mg/day) (n = 19) or metformin (1500 mg/day) (n = 20). Blood samples were collected at baseline and 12 weeks after treatment and analysed for specific surface proteins (ICAM-1, VCAM-1, PECAM-1, E-selectin and endoglin) expressed by circulating EMPs using flow cytometry. Results In the empagliflozin group, ICAM-1 (P = 0.006), E-selectin (P = 0.016) and VCAM-1 (P = 0.001) EMPs increased significantly following 12 weeks of treatment, but no changes were seen in PECAM-1 (P = 0.93) or endoglin (P = 0.13) EMPs. In the metformin group, VCAM-1 EMPs (P < 0.001) increased significantly after 12 weeks of treatment, whereas all other EMPs remained unchanged. When data were expressed as percentage change from baseline in each group, no significant differences were seen between groups for any biomarker (P-values from 0.22 to 0.80). Conclusions Short-term administration of empagliflozin and metformin in overweight/obese women with PCOS appear to increase EMPs expressed by endothelial cells during their activation. |
---|---|
AbstractList | Context Endothelial microparticles (EMPs) are novel, surrogate biomarkers of endothelial function and have been shown to be elevated in women with polycystic ovary syndrome (PCOS). It remains poorly understood how pharmacological options for managing PCOS affect EMP levels. Objective To characterise and compare the effects of empagliflozin vs metformin on the circulating levels of EMPs in overweight/obese women with PCOS. Methods This was a randomised, comparative, 12-week single-centre trial conducted at the Academic Diabetes, Endocrinology and Metabolism Research Centre, Hull, UK. This analysis includes data from 39 overweight/obese women with PCOS who completed the study and were randomised to empagliflozin (15 mg/day) (n = 19) or metformin (1500 mg/day) (n = 20). Blood samples were collected at baseline and 12 weeks after treatment and analysed for specific surface proteins (ICAM-1, VCAM-1, PECAM-1, E-selectin and endoglin) expressed by circulating EMPs using flow cytometry. Results In the empagliflozin group, ICAM-1 (P = 0.006), E-selectin (P = 0.016) and VCAM-1 (P = 0.001) EMPs increased significantly following 12 weeks of treatment, but no changes were seen in PECAM-1 (P = 0.93) or endoglin (P = 0.13) EMPs. In the metformin group, VCAM-1 EMPs (P < 0.001) increased significantly after 12 weeks of treatment, whereas all other EMPs remained unchanged. When data were expressed as percentage change from baseline in each group, no significant differences were seen between groups for any biomarker (P-values from 0.22 to 0.80). Conclusions Short-term administration of empagliflozin and metformin in overweight/obese women with PCOS appear to increase EMPs expressed by endothelial cells during their activation. Endothelial microparticles (EMPs) are novel, surrogate biomarkers of endothelial function and have been shown to be elevated in women with polycystic ovary syndrome (PCOS). It remains poorly understood how pharmacological options for managing PCOS affect EMP levels. To characterise and compare the effects of empagliflozin vs metformin on the circulating levels of EMPs in overweight/obese women with PCOS. This was a randomised, comparative, 12-week single-centre trial conducted at the Academic Diabetes, Endocrinology and Metabolism Research Centre, Hull, UK. This analysis includes data from 39 overweight/obese women with PCOS who completed the study and were randomised to empagliflozin (15 mg/day) (n = 19) or metformin (1500 mg/day) (n = 20). Blood samples were collected at baseline and 12 weeks after treatment and analysed for specific surface proteins (ICAM-1, VCAM-1, PECAM-1, E-selectin and endoglin) expressed by circulating EMPs using flow cytometry. In the empagliflozin group, ICAM-1 (P = 0.006), E-selectin (P = 0.016) and VCAM-1 (P = 0.001) EMPs increased significantly following 12 weeks of treatment, but no changes were seen in PECAM-1 (P = 0.93) or endoglin (P = 0.13) EMPs. In the metformin group, VCAM-1 EMPs (P < 0.001) increased significantly after 12 weeks of treatment, whereas all other EMPs remained unchanged. When data were expressed as percentage change from baseline in each group, no significant differences were seen between groups for any biomarker (P-values from 0.22 to 0.80). Short-term administration of empagliflozin and metformin in overweight/obese women with PCOS appear to increase EMPs expressed by endothelial cells during their activation. Context: Endothelial microparticles (EMPs) are novel, surrogate biomarkers of endothelial function and have been shown to be elevated in women with polycystic ovary syndrome (PCOS). It remains poorly understood how pharmacological options for managing PCOS affect EMP levels. Objective: To characterise and compare the effects of empagliflozin vs metf ormin on the circulating levels of EMPs in overweight/obese women with PCOS. Methods: This was a randomised, comparative, 12-week single-centre trial conducted at the Academic Diabetes, Endocrinology and Metabolism Research Centre, Hull, UK. This analysis includes data from 39 overweight/obese women with PCOS who completed the study and were randomised to empagliflozin (15 mg/day) (n = 19) or metformin (1500 mg/day) (n = 20). Blood samples were collected at baseline and 12 weeks after treatment and analysed for specific surface proteins (ICAM-1, VCAM-1, PECA M-1, E-selectin and endoglin) expressed by circulating EMPs using flow cytometry. Results: In the empagliflozin group, ICAM-1 (P = 0.006), E-selectin (P = 0.016) and VCAM-1 (P = 0.001) EMPs increased significantly following 12 weeks of treatment, but no changes were seen in PECAM-1 (P = 0.93) or endoglin (P = 0.13) EMPs. In the metformin group, VCAM-1 EMPs (P < 0.001) increased significantly after 12 weeks of treatment, w hereas all other EMPs remained unchanged. When data were expressed as percentage change from baseline in each group, no significant differences were seen between groups for any biomarker (P-values from 0.22 to 0.80). Conclusions: Short-term administration of empagliflozin and metformin in ove rweight/ obese women with PCOS appear to increase EMPs expressed by endothelial cells during their activation. CONTEXTEndothelial microparticles (EMPs) are novel, surrogate biomarkers of endothelial function and have been shown to be elevated in women with polycystic ovary syndrome (PCOS). It remains poorly understood how pharmacological options for managing PCOS affect EMP levels. OBJECTIVETo characterise and compare the effects of empagliflozin vs metformin on the circulating levels of EMPs in overweight/obese women with PCOS. METHODSThis was a randomised, comparative, 12-week single-centre trial conducted at the Academic Diabetes, Endocrinology and Metabolism Research Centre, Hull, UK. This analysis includes data from 39 overweight/obese women with PCOS who completed the study and were randomised to empagliflozin (15 mg/day) (n = 19) or metformin (1500 mg/day) (n = 20). Blood samples were collected at baseline and 12 weeks after treatment and analysed for specific surface proteins (ICAM-1, VCAM-1, PECAM-1, E-selectin and endoglin) expressed by circulating EMPs using flow cytometry. RESULTSIn the empagliflozin group, ICAM-1 (P = 0.006), E-selectin (P = 0.016) and VCAM-1 (P = 0.001) EMPs increased significantly following 12 weeks of treatment, but no changes were seen in PECAM-1 (P = 0.93) or endoglin (P = 0.13) EMPs. In the metformin group, VCAM-1 EMPs (P < 0.001) increased significantly after 12 weeks of treatment, whereas all other EMPs remained unchanged. When data were expressed as percentage change from baseline in each group, no significant differences were seen between groups for any biomarker (P-values from 0.22 to 0.80). CONCLUSIONSShort-term administration of empagliflozin and metformin in overweight/obese women with PCOS appear to increase EMPs expressed by endothelial cells during their activation. |
Author | Rigby, Alan S Papageorgiou, Maria Kilpatrick, Eric S Madden, Leigh A Javed, Zeeshan Atkin, Stephen L Sathyapalan, Thozhukat |
AuthorAffiliation | Department of Pathology, Sidra Medical and Research Center, Doha, Qatar Hull York Medical School, University of Hull, Hull, UK School of Life Sciences, University of Hull, Hull, UK Department of Academic Diabetes, Endocrinology and Metabolism, Hull York Medical School, University of Hull, Hull, UK Department of Endocrinology and Diabetes, Pakistan Kidney and Liver Institute and Research Centre, Knowledge City, Lahore, Pakistan Division of Bone Diseases, Geneva University Hospitals and Faculty of Medicine, University of Geneva, Geneva, Switzerland Royal College of Surgeons in Ireland, Al Sayh, Bahrain |
AuthorAffiliation_xml | – name: Hull York Medical School, University of Hull, Hull, UK – name: Royal College of Surgeons in Ireland, Al Sayh, Bahrain – name: Department of Endocrinology and Diabetes, Pakistan Kidney and Liver Institute and Research Centre, Knowledge City, Lahore, Pakistan – name: Department of Academic Diabetes, Endocrinology and Metabolism, Hull York Medical School, University of Hull, Hull, UK – name: School of Life Sciences, University of Hull, Hull, UK – name: Division of Bone Diseases, Geneva University Hospitals and Faculty of Medicine, University of Geneva, Geneva, Switzerland – name: Department of Pathology, Sidra Medical and Research Center, Doha, Qatar |
Author_xml | – sequence: 1 givenname: Zeeshan surname: Javed fullname: Javed, Zeeshan organization: Department of Endocrinology and Diabetes, Pakistan Kidney and Liver Institute and Research Centre, Knowledge City, Lahore, Pakistan – sequence: 2 givenname: Maria surname: Papageorgiou fullname: Papageorgiou, Maria organization: Division of Bone Diseases, Geneva University Hospitals and Faculty of Medicine, University of Geneva, Geneva, Switzerland – sequence: 3 givenname: Leigh A surname: Madden fullname: Madden, Leigh A organization: School of Life Sciences, University of Hull, Hull, UK – sequence: 4 givenname: Alan S surname: Rigby fullname: Rigby, Alan S organization: Hull York Medical School, University of Hull, Hull, UK – sequence: 5 givenname: Eric S surname: Kilpatrick fullname: Kilpatrick, Eric S organization: Department of Pathology, Sidra Medical and Research Center, Doha, Qatar – sequence: 6 givenname: Stephen L surname: Atkin fullname: Atkin, Stephen L organization: Royal College of Surgeons in Ireland, Al Sayh, Bahrain – sequence: 7 givenname: Thozhukat orcidid: 0000-0003-3544-2231 surname: Sathyapalan fullname: Sathyapalan, Thozhukat email: Thozhukat.Sathyapalan@hyms.ac.uk organization: Department of Academic Diabetes, Endocrinology and Metabolism, Hull York Medical School, University of Hull, Hull, UK |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/32449697$$D View this record in MEDLINE/PubMed |
BookMark | eNp9kstuEzEUQEeoiD7ohg9AXiKkofb4ORskFIVSqRKbsrbGnuuMK8842JNEYcWn45BQtRu88eMeH1_b97I6m-IEVfWO4E-EU3yzXNQNrjGR9FV10WDW1lQQdvZsfF5d5_yIS1NEKIrfVOe0YawVrbyofj8MgMA5sHNG0SEY190qeBfiLz-hbUYjzC6msUzihGDq4zxA8F1Ao7cprrs0exsgowOwhbQDvxrmm2ggA9rFESa08_OA1jHs7T4XuGBd2qO8n_pU4m-r164LGa5P_VX14-vyYfGtvv9-e7f4cl8bpvhcc-lsz0uajipnFFWMCNJyCYIooJgQiltijGpMLzFYYEQqzAhvZdkhnKFX1d3R28fuUa-TH0sWOnZe_12IaaVPd9E9ltYKxY3rCXNKKCah4a1x3ClJlSiuz0fXemNG6C1Mc-rCC-nLyOQHvYpbLSlnkrZF8OEkSPHnBvKsR58thNBNEDdZNwwLLjkRtKAfj2h57ZwTuKdjCNaHCtDLhW6wPlRAgd8_T-wJ_fffBcBHwPiYrS_peedt9z_nH-siwHA |
CitedBy_id | crossref_primary_10_1530_JOE_21_0449 crossref_primary_10_1016_j_lfs_2024_122876 crossref_primary_10_3390_ijms21249554 crossref_primary_10_1136_bmjmed_2023_000548 crossref_primary_10_3357_AMHP_6247_2023 crossref_primary_10_3389_fendo_2022_1003238 crossref_primary_10_1007_s00404_020_05696_y crossref_primary_10_1007_s40265_022_01779_z crossref_primary_10_1136_bmjopen_2021_058260 crossref_primary_10_3389_fendo_2020_581839 crossref_primary_10_2174_1573404818666220208110240 crossref_primary_10_1016_j_cca_2022_06_019 crossref_primary_10_3389_fendo_2022_826604 crossref_primary_10_51847_eilLCorjfQ |
ContentType | Journal Article |
Copyright | 2020 The authors 2020 The authors 2020 The authors |
Copyright_xml | – notice: 2020 The authors – notice: 2020 The authors 2020 The authors |
DBID | NPM AAYXX CITATION 7X8 5PM DOA |
DOI | 10.1530/EC-20-0173 |
DatabaseName | PubMed CrossRef MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
DatabaseTitle | PubMed CrossRef MEDLINE - Academic |
DatabaseTitleList | PubMed MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Anatomy & Physiology |
DocumentTitleAlternate | Empagliflozin and metformin in PCOS Z Javed et al |
EISSN | 2049-3614 |
EndPage | 569 |
ExternalDocumentID | oai_doaj_org_article_d07cc685bfd14f86847e259bf5f87386 10_1530_EC_20_0173 32449697 |
Genre | Journal Article |
GroupedDBID | 53G 5VS AAFZV ABLYK ABSGY ABSQV ADBBV ADRAZ AIPOO ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL BCNDV BTFSW DIK EBS EE- EJD F9R FRJ GROUPED_DOAJ GX1 HYE INIJC IPNFZ KQ8 M48 M~E OK1 RHF RIG RPM TBS H13 NPM PGMZT AAYXX CITATION 7X8 5PM |
ID | FETCH-LOGICAL-b485t-57fcd5fecf38fb8384161957e618e30113091bb82bd70ece4178041597cf36fb3 |
IEDL.DBID | RPM |
ISSN | 2049-3614 |
IngestDate | Tue Oct 22 15:16:37 EDT 2024 Tue Sep 17 20:58:29 EDT 2024 Sat Aug 17 02:06:44 EDT 2024 Fri Dec 06 02:44:49 EST 2024 Sat Sep 28 08:20:49 EDT 2024 Sun Jan 07 07:18:53 EST 2024 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 6 |
Keywords | empagliflozin endothelial microparticles metformin polycystic ovary syndrome SGLT2 inhibitors |
Language | English |
License | This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-b485t-57fcd5fecf38fb8384161957e618e30113091bb82bd70ece4178041597cf36fb3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ORCID | 0000-0003-3544-2231 |
OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7354739/ |
PMID | 32449697 |
PQID | 2406575163 |
PQPubID | 23479 |
PageCount | 7 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_d07cc685bfd14f86847e259bf5f87386 pubmedcentral_primary_oai_pubmedcentral_nih_gov_7354739 proquest_miscellaneous_2406575163 crossref_primary_10_1530_EC_20_0173 pubmed_primary_32449697 bioscientifica_primary_10_1530_EC_20_0173 |
PublicationCentury | 2000 |
PublicationDate | 2020-06-01 |
PublicationDateYYYYMMDD | 2020-06-01 |
PublicationDate_xml | – month: 06 year: 2020 text: 2020-06-01 day: 01 |
PublicationDecade | 2020 |
PublicationPlace | England |
PublicationPlace_xml | – name: England – name: Bristol |
PublicationTitle | Endocrine Connections |
PublicationTitleAlternate | Endocr Connect |
PublicationYear | 2020 |
Publisher | Bioscientifica Ltd Bioscientifica |
Publisher_xml | – name: Bioscientifica Ltd – name: Bioscientifica |
SSID | ssj0000816830 |
Score | 2.2645144 |
Snippet | Context Endothelial microparticles (EMPs) are novel, surrogate biomarkers of endothelial function and have been shown to be elevated in women with polycystic... Endothelial microparticles (EMPs) are novel, surrogate biomarkers of endothelial function and have been shown to be elevated in women with polycystic ovary... CONTEXTEndothelial microparticles (EMPs) are novel, surrogate biomarkers of endothelial function and have been shown to be elevated in women with polycystic... Context: Endothelial microparticles (EMPs) are novel, surrogate biomarkers of endothelial function and have been shown to be elevated in women with polycystic... |
SourceID | doaj pubmedcentral proquest crossref pubmed bioscientifica |
SourceType | Open Website Open Access Repository Aggregation Database Index Database Publisher |
StartPage | 563 |
SubjectTerms | empagliflozin endothelial microparticles metformin polycystic ovary syndrome sglt2 inhibitors |
SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Nj9MwELXQnjiAgOWjy4eMQEgcoiaxHdvHpepqhQQnVtqbtY7HUKl1qm0XqZz46cw46apBCC4c27qKm3kZv7Ff3zD2VgXkCLIMpJ4KhYSqLZAcyQLAehG0tE3uPPfpc3N-IT9eqsuDVl-kCevtgfsbNw2lbtvGKB9DJaNpMJsCUnYfVTTUsDJn37I-KKZyDqZ2ErnRSI0UuBC4CA3epEqU0_kMwYFFNDVLv-cXvWtkluaMl6fs4v8n6vm7gvJgSTp7wO4PXJKf9r_hIbsD6RE7Pk1YR692_B3P6s68bX7MfiIe-CDe4F3kgGng63IRl92PReLfN3wFW-Kv-KJLHFKgf2YtEZx8RZK99V5Ax2lAFlNTVT_tPGyAZxsHTlu6fN0td-2OzJ9x2NX1ju8tER6zi7P5l9l5MXRfKLw0alsoHdugcFpRmOiNoPPJyioNTWWA0oJAquG9qX3QJbQgq97LyGr8RhO9eMKOUpfgGeNQCYl4wErSkBdOtGCk9BasqKA02k7Y-3EU3Lq32nBUomDE3Hzm6tJRxCbszT5Afx31gWJ3O4JMtPMbCC033DH3L2hN2Ot95B0-dHSScpWgu9k4okF0YNXghZ72SLi9FDJURLjVE6ZHGBnNZfxJWnzLxt5aUCdoe_I_Jv-c3a1payBvGL1gR9vrG3iJ_GnrX-VH5RcTgxlf priority: 102 providerName: Directory of Open Access Journals – databaseName: Scholars Portal Journals: Open Access dbid: M48 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1Nb9QwELVKuYAEAsrH8iUjEBKH0CR2YvuAUFltVSGVEyv1FtXJuF0p6yy726rhxE9nxkkqgirEMYmjJJ6x54398oaxd1mFGEHGFbGnqkhCUkYIjmQEYKyolDR5qDx3_C0_msuvJ9nJDhvqd_YduLkxtaN6UvN1_fHqR_sZB_ynUL1HxPuzKdoac2IlbrHbKUZEonYd9zA_zMhUXCKUHUkREEcCQ1KvVDq-_S67ZxedhmQg6oyDVdD0vwmI_s2n_CNAHT5g93tkyQ86V3jIdsA_YnsHHrPqZcvf88D1DIvoe-wXegfvqRy8cRxwUjirF65ufi48v9zwJWwJzeJB4zn4iv7TqtFV-ZIIfKuBTsepQaBWU46_31jYAA-iDpwWePmqqduyJSlobHa6bvkgkPCYzQ9n36dHUV-LIbJSZ9soU66sMnwtJ7SzWtBuZWIyBXmigSYJgcDDWp3aSsVQgkw6ZSOj8I7cWfGE7frGwzPGIRESvQPzSk3KOM6AltIaMCKBWCszYR_GVihWnfBGQQkLWqyYTYs0LshiE_Z2MNA_W30h2123IEntcKJZnxV9jxVVrMoy15l1VSKdzjFsA-aG1mVOU2XUCXszWL7AIUj7KqcemotNQaCItq9yfNDTzhOuH4V4Ff3dqAlTIx8Zvcv4il-cB5lvJagutHn-X5_4gt1JaSUgrA-9ZLvb9QW8Qri0ta_DWPgNs0gUIg priority: 102 providerName: Scholars Portal |
Title | The effects of empagliflozin vs metformin on endothelial microparticles in overweight/obese women with polycystic ovary syndrome |
URI | http://dx.doi.org/10.1530/EC-20-0173 https://www.ncbi.nlm.nih.gov/pubmed/32449697 https://search.proquest.com/docview/2406575163 https://pubmed.ncbi.nlm.nih.gov/PMC7354739 https://doaj.org/article/d07cc685bfd14f86847e259bf5f87386 |
Volume | 9 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Nb9QwELXanjiAgPKxfFRGICQO6SZrO3aOZbWlQlrEgUp7i-pkXCIlzmp3i7Sc-OnMOEnVIMSBS6QkjmJ5XuyZ8csbxt6pEn0EGZfEniojCUkRoXMkI4DMilLLLA2V55Zf0otL-XmlVgdMDf_CBNJ-YatTXzenvvoeuJXrppgOPLHp1-VcC6qYm00P2SEuv3dC9DD9UiUJEfdSpErE08UcsYAxs6aiOehAYAdI4-m-rTq9yEDKGS9MQb__b07nn9zJO4vR-UP2oPci-VnX20fsAPxjdnzmMYJu9vw9D7zOkDA_Zr8QCbynbfDWccAJ4LquXN3-rDz_seUN7MhzxZPWc_Al_ZNVIyx5Q2S99TAknBoEGjXF89PWwhZ4EHDglMzl67beF3uSfcZmV5s9H8QQnrDL88W3-UXU112IrDRqFyntilJht5wwzhpBO5NJpjSkiQGaEAQ6GdaamS11DAXIpFMxyjQ-kTornrIj33p4zjgkQiISMIY0pILjMjBS2gwykUBsdDZhH8ZWyNedyEZOwQkaL1_M81mck_Em7O1goH-2-ki2u21B8tnhQru5zvsRy8tYF0VqlHVlIp1JcYkGjAOtU85QFdQJezNYPsfPjfZQrjy0N9ucHCDaqkrxRc86JNy-aoDWhOkRRkZ9Gd9BhAdJ7x7RL_77yZfs3owyASE_9Iod7TY38BrdpZ09CWkGPH5aJXhcSnMSPpjfcKUa4A |
link.rule.ids | 230,314,727,780,784,864,885,2102,2221,24318,27924,27925,53791,53793 |
linkProvider | National Library of Medicine |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Nb9QwELVKOcABBJSPLV9GICQOaZK1HTvHstpqgW7FoZV6i-pkXCLlY7W7rbSc-OnMOEnVRYgDxySOYmVe7Df2yxvGPqgCOYKMClJPFYGEOA-QHMkAILWi0DJNfOW5-UkyO5Nfz9X5DlPDvzBetJ_b8qCp6oOm_OG1lYs6DwedWPh9PtGCKuam4R12VwmdxreSdD8AUy0JEfVmpEpE4XSCaMCsWVPZHKQQ2AVyeXpgy84x0stytqcm7-D_N9r5p3ry1nR09Ig97HkkP-z6-5jtQPOE7R02mEPXG_6Re2WnXzLfY78QC7wXbvDWccAh4LIqXdX-LBt-veI1rIm74kHbcGgK-iurQmDymuR6i-GlcGrghdSU0YethRVwb-HAaTmXL9pqk2_I-BmbXSw3fLBDeMrOjqank1nQV14IrDRqHSjt8kJht5wwzhpBe5NxqjQksQEaEgTSDGvN2BY6ghxk3PkYpRrvSJwVz9hu0zbwgnGIhUQsYBZpyAfHpWCktCmkIobI6HTEPm1HIVt0NhsZpScYvGw6ycZRRsEbsfdDgP7Z6jPF7qYFGWj7E-3yMuvfWFZEOs8To6wrYulMgpM0YCZonXKG6qCO2Lsh8hl-cLSLctFAe7XKiALRZlWCD3reIeHmUQO0RkxvYWSrL9tXEOPe1LvH9P5_3_mW3Zudzo-z4y8n316y-2NaF_CrRa_Y7np5Ba-RPK3tG_-p_AZ-kht1 |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Nb9QwELWgSIgDFVAoy6cRCIlDmmTtJM6xLLsqH616oFJvVp2MS6R8aXdbaTnx05lxkmqDEAeOSRzFyrzYb-yXN4y9i3LkCDLIST2VexLCzENyJD2A1Ig8kWnsKs8dn8RHZ_LLeXS-VerLifYzUxzUZXVQFz-ctrKtMn_Qifmnx7NEUMXc1G9z699mdyKBINtK1N0gTPUkRNAbkkYi8OczRARmzgmVzkEagd0gp6f7puhcI500Zzw9ORf_v1HPPxWUW1PS4gHb7bkkP-z6_JDdgvoR2zusMY-uNvw9d-pOt2y-x34hHngv3uCN5YDDwGVZ2LL5WdT8esUrWBN_xYOm5lDn9GdWieDkFUn22uHFcGrgxNSU1fuNgRVwZ-PAaUmXt025yTZk_ozNLpYbPlgiPGZni_n32ZHXV1_wjFTR2osSm-URdssKZY0StD8ZplECcaiAhgWBVMMYNTV5EkAGMuy8jNIE74itEU_YTt3U8JRxCIVEPGAmqcgLx6agpDQppCKEQCXphH0YR0G3ndWGphQFg6fnMz0NNAVvwt4OAfpnq48Uu5sWZKLtTjTLS92_MZ0HSZbFKjI2D6VVMU7UgNmgsZFVVAt1wt4Mkdf40dFOykUNzdVKEw2iDasYH7TfIeHmUQO0JiwZYWTUl_EVxLkz9u5x_ey_73zN7p5-Wuhvn0--Pmf3prQ04BaMXrCd9fIKXiJ_WptX7kv5DXlgHIg |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+effects+of+empagliflozin+vs+metformin+on+endothelial+microparticles+in+overweight%2Fobese+women+with+polycystic+ovary+syndrome&rft.jtitle=Endocrine+Connections&rft.au=Javed%2C+Zeeshan&rft.au=Papageorgiou%2C+Maria&rft.au=Madden%2C+Leigh+A&rft.au=Rigby%2C+Alan+S&rft.date=2020-06-01&rft.issn=2049-3614&rft.eissn=2049-3614&rft.volume=9&rft.issue=6&rft.spage=563&rft.epage=569&rft_id=info:doi/10.1530%2FEC-20-0173&rft.externalDBID=n%2Fa&rft.externalDocID=10_1530_EC_20_0173 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2049-3614&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2049-3614&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2049-3614&client=summon |